Arkadios Wealth Advisors Grows Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Arkadios Wealth Advisors raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,702 shares of the life sciences company’s stock after acquiring an additional 433 shares during the period. Arkadios Wealth Advisors’ holdings in Illumina were worth $1,265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina in the 2nd quarter worth about $34,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter worth about $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Illumina during the 2nd quarter worth approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 0.4 %

ILMN opened at $141.95 on Monday. The stock’s 50 day moving average price is $134.53 and its 200 day moving average price is $121.57. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $22.61 billion, a P/E ratio of -7.41 and a beta of 1.15. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $151.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. As a group, research analysts predict that Illumina, Inc. will post 3.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. Barclays boosted their price objective on shares of Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 15th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 17th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Robert W. Baird raised their target price on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Finally, TD Cowen upgraded shares of Illumina from a “hold” rating to a “buy” rating and lifted their price target for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $154.33.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.